Compare Adaptive Biotechnologies Corp (ADPT) vs Xylem, Inc. (XYL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Xylem, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Xylem, Inc. trades at $118.41 (market cap $28.68B). The key difference: Xylem, Inc. is far larger — about 8.6× Adaptive Biotechnologies Corp's market cap, and Xylem, Inc. pays a 1.43% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | XYL | |
|---|---|---|
Market Cap | $3.33B | $28.68B |
Sector | Health | Industrials |
52-Week High | $22.37 | $152.95 |
52-Week Low | $10.24 | $106.34 |
Enterprise Value | $3.19B | $29.93B |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Xylem (XYL) trades at $120.65, up 2.14% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income margin improving to 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing its position in water technology solutions.
The stock offers upside to the $153.14 consensus price target, driven by steady earnings growth and margin expansion. Risks include execution challenges in a competitive market and potential macroeconomic headwinds affecting industrial demand. Analyst sentiment is mixed but leans positive with 47.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
